Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Alpha Cognition Inc ACOG

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.


NDAQ:ACOG - Post by User

Post by culturedpiggy01on Dec 16, 2021 4:45pm
178 Views
Post# 34238511

Pharma Exec's on marketing and comm. in post Covid-19 era

Pharma Exec's on marketing and comm. in post Covid-19 era
came across this great article summarizing a conversation between leading pharmaceutical executives including ACOG.v 's COO Lauren D’Angelo about delivering information and communication channels in the post COVID-19 era and its impact on sales and marketing. Read here: https://www.pharmexec.com/view/the-future-of-sales-and-marketing-how-to-deliver-information-in-the-era-of-covid-19
 
td, $ACOG.v trading at $1.21 with market cap at $74.41 M
<< Previous
Bullboard Posts
Next >>